{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:00:33Z","timestamp":1793948433221,"version":"4.8.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T00:00:00Z","timestamp":1734134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12072-024-10748-5","type":"journal-article","created":{"date-parts":[[2024,12,14]],"date-time":"2024-12-14T10:18:30Z","timestamp":1734171510000},"page":"384-394","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["MAFLD but not MASLD increases risk of all-cause mortality in regional Australia, with components of metabolic syndrome exacerbating factors: 20\u00a0year longitudinal, cohort study"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6427-6140","authenticated-orcid":false,"given":"Karl","family":"Vaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Kemp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammar","family":"Majeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Lubel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianna J.","family":"Magliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen M.","family":"Glenister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Bourke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart K.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,14]]},"reference":[{"key":"10748_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.002","author":"MH Le","year":"2019","unstructured":"Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, et al. Global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019. https:\/\/doi.org\/10.1016\/j.cgh.2021.12.002","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10748_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S0002-9343(99)00271-5","volume":"107","author":"G Marchesini","year":"1999","unstructured":"Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, et al. Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999;107(5):450\u2013455","journal-title":"Am J Med"},{"issue":"17","key":"10748_CR3","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1056\/NEJMoa2029349","volume":"385","author":"AJ Sanyal","year":"2021","unstructured":"Sanyal AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, Diehl A, Dasarathy S, et al. Prospective study of outcomes in adults with nonalcoholic fatty liver disease. N Engl J Med. 2021;385(17):1559\u20131569","journal-title":"N Engl J Med"},{"issue":"1","key":"10748_CR4","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1053\/j.gastro.2005.04.014","volume":"129","author":"LA Adams","year":"2005","unstructured":"Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology. 2005;129(1):113\u2013121","journal-title":"Gastroenterology"},{"key":"10748_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d6891","volume":"343","author":"M Lazo","year":"2011","unstructured":"Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343: d6891","journal-title":"BMJ"},{"issue":"6","key":"10748_CR6","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1016\/j.jhep.2021.07.035","volume":"75","author":"D Kim","year":"2021","unstructured":"Kim D, Konyn P, Sandhu KK, Dennis BB, Cheung AC, Ahmed A. Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States. J Hepatol. 2021;75(6):1284\u20131291","journal-title":"J Hepatol"},{"issue":"5","key":"10748_CR7","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1002\/hep.32499","volume":"76","author":"ZM Younossi","year":"2022","unstructured":"Younossi ZM, Paik JM, Al Shabeeb R, Golabi P, Younossi I, Henry L. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology. 2022;76(5):1423\u20131437","journal-title":"Hepatology"},{"key":"10748_CR8","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000696","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multi-society Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000696","journal-title":"J Hepatol"},{"key":"10748_CR9","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52189","author":"K Vaz","year":"2023","unstructured":"Vaz K, Kemp WW, Majeed A, Lubel J, Magliano D, Glenister K, et al. Steatotic liver disease in rural and regional Victoria, according to the NAFLD and newer diagnostic criteria: retrospective cohort analyses of 2001\u201303 and 2016\u201318 data. Med J Aust. 2023. https:\/\/doi.org\/10.5694\/mja2.52189","journal-title":"Med J Aust"},{"issue":"2","key":"10748_CR10","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JC, Wong GL, Wong VW, Yip TC. Can we use old NAFLD data under the new MASLD definition? J Hepatol. 2024;80(2):e54\u2013e56","journal-title":"J Hepatol"},{"issue":"5","key":"10748_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1111\/j.1464-5491.2008.02408.x","volume":"25","author":"MC Devers","year":"2008","unstructured":"Devers MC, Campbell S, Shaw J, Zimmet P, Simmons D. Should liver function tests be included in definitions of metabolic syndrome? Evidence from the association between liver function tests, components of metabolic syndrome and prevalent cardiovascular disease. Diabet Med. 2008;25(5):523\u2013529","journal-title":"Diabet Med"},{"issue":"3","key":"10748_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.diabres.2005.04.004","volume":"70","author":"D Simmons","year":"2005","unstructured":"Simmons D, McKenzie A, Eaton S, Shaw J, Zimmet P. Prevalence of diabetes in rural Victoria. Diabetes Res Clin Pract. 2005;70(3):287\u2013290","journal-title":"Diabetes Res Clin Pract"},{"key":"10748_CR13","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","volume":"6","author":"G Bedogni","year":"2006","unstructured":"Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6:33","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10748_CR14","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73(1):202\u2013209","journal-title":"J Hepatol"},{"issue":"6","key":"10748_CR15","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"European Association for the Study of the Liver","year":"2016","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388\u20131402","journal-title":"J Hepatol"},{"issue":"1","key":"10748_CR16","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46(1):S19\u2013S40","journal-title":"Diabetes Care"},{"issue":"16","key":"10748_CR17","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1161\/CIRCULATIONAHA.109.192644","volume":"120","author":"KG Alberti","year":"2009","unstructured":"Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640\u20131645","journal-title":"Circulation"},{"issue":"5","key":"10748_CR18","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","volume":"156","author":"L Castera","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019;156(5):1264\u201381.e4","journal-title":"Gastroenterology"},{"key":"10748_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154183","volume":"111S","author":"S Kechagias","year":"2020","unstructured":"Kechagias S, Nasr P, Blomdahl J, Ekstedt M. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease. Metabolism. 2020;111S: 154183","journal-title":"Metabolism"},{"issue":"1","key":"10748_CR20","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73\u201384","journal-title":"Hepatology"},{"issue":"1","key":"10748_CR21","doi-asserted-by":"publisher","first-page":"11124","DOI":"10.1038\/s41598-019-47687-3","volume":"9","author":"Y Liu","year":"2019","unstructured":"Liu Y, Zhong GC, Tan HY, Hao FB, Hu JJ. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep. 2019;9(1):11124","journal-title":"Sci Rep"},{"issue":"5","key":"10748_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Stal P, Kechagias S, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology. 2015;61(5):1547\u20131554","journal-title":"Hepatology"},{"issue":"2","key":"10748_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.2337\/dc17-1590","volume":"41","author":"SH Wild","year":"2018","unstructured":"Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, et al. Cardiovascular disease, cancer, and mortality among people with type 2 diabetes and alcoholic or nonalcoholic fatty liver disease hospital admission. Diabetes Care. 2018;41(2):341\u2013347","journal-title":"Diabetes Care"},{"issue":"10","key":"10748_CR24","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1016\/j.amjcard.2017.07.107","volume":"120","author":"M Keskin","year":"2017","unstructured":"Keskin M, Hayiroglu MI, Uzun AO, Guvenc TS, Sahin S, Kozan O. Effect of nonalcoholic fatty liver disease on in-hospital and long-term outcomes in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017;120(10):1720\u20131726","journal-title":"Am J Cardiol"},{"issue":"10","key":"10748_CR25","doi-asserted-by":"publisher","first-page":"2172","DOI":"10.1016\/j.cgh.2021.05.029","volume":"19","author":"VH Nguyen","year":"2021","unstructured":"Nguyen VH, Le MH, Cheung RC, Nguyen MH. Differential clinical characteristics and mortality outcomes in persons with NAFLD and\/or MAFLD. Clin Gastroenterol Hepatol. 2021;19(10):2172\u201381.e6","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"10748_CR26","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1210\/clinem\/dgab644","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol Metab. 2022;107(2):e745\u2013e755","journal-title":"J Clin Endocrinol Metab"},{"key":"10748_CR27","doi-asserted-by":"publisher","DOI":"10.4093\/dmj.2021.0327","author":"KS Kim","year":"2023","unstructured":"Kim KS, Hong S, Ahn HY, Park CY. Metabolic dysfunction-associated fatty liver disease and mortality: a population-based cohort study. Diabetes Metab J. 2023. https:\/\/doi.org\/10.4093\/dmj.2021.0327","journal-title":"Diabetes Metab J"},{"issue":"10290","key":"10748_CR28","doi-asserted-by":"publisher","first-page":"2212","DOI":"10.1016\/S0140-6736(20)32511-3","volume":"397","author":"EE Powell","year":"2021","unstructured":"Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet. 2021;397(10290):2212\u20132224","journal-title":"Lancet"},{"issue":"8","key":"10748_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","volume":"65","author":"Y Fazel","year":"2016","unstructured":"Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65(8):1017\u20131025","journal-title":"Metabolism"},{"issue":"8","key":"10748_CR30","doi-asserted-by":"publisher","first-page":"358","DOI":"10.5694\/mja2.52104","volume":"219","author":"J O'Beirne","year":"2023","unstructured":"O\u2019Beirne J, Skoien R, Leggett BA, Hartel GF, Gordon LG, Powell EE, et al. Diabetes mellitus and the progression of non-alcoholic fatty liver disease to decompensated cirrhosis: a retrospective cohort study. Med J Aust. 2023;219(8):358\u2013365","journal-title":"Med J Aust"},{"issue":"4","key":"10748_CR31","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.cgh.2020.06.045","volume":"19","author":"S Petta","year":"2021","unstructured":"Petta S, Sebastiani G, Vigano M, Ampuero J, Wai-Sun Wong V, Boursier J, et al. Monitoring occurrence of liver-related events and survival by transient elastography in patients with nonalcoholic fatty liver disease and compensated advanced chronic liver disease. Clin Gastroenterol Hepatol. 2021;19(4):806\u201315.e5","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10748_CR32","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s12072-020-10094-2","volume":"14","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int. 2020;14(6):889\u2013919","journal-title":"Hepatol Int"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10748-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-024-10748-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-024-10748-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T05:35:59Z","timestamp":1744781759000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-024-10748-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,14]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10748"],"URL":"https:\/\/doi.org\/10.1007\/s12072-024-10748-5","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,14]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Karl Vaz, William Kemp, Ammar Majeed, John Lubel, Dianna J. Magliano, Kristen M. Glenister, Lisa Bourke, David Simmons, Stuart K. Roberts declare they have no relevant financial or non-financial conflict of interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The Crossroads study was approved by the Goulburn Valley Health Human Research Ethics Committee (GCH-3\/99), while the current follow-up study has been approved by the Alfred Health Ethics Committee (project 310\/22).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Participants in the Crossroads study provided informed consent to participate. Individual informed consent for the current study on outcomes was waived by the Alfred Health Ethics Committee.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}